Inflammation in renal transplantation

Sadollah Abedini, Ingar Holme, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hans-Hellmut Neumayer, Carola Grønhagen-Riska, Patrice Ambühl, Hallvard Holdaas, ALERT study group, Sadollah Abedini, Ingar Holme, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hans-Hellmut Neumayer, Carola Grønhagen-Riska, Patrice Ambühl, Hallvard Holdaas, ALERT study group

Abstract

Background and objectives: Renal transplant recipients experience premature cardiovascular disease and death. The association of inflammation, all-cause mortality, and cardiovascular events in renal transplant recipients has not been examined in a large prospective controlled trial.

Design, setting, participants, & measurements: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin on cardiovascular and renal outcomes in 2102 renal transplant recipients. Patients initially randomized to fluvastatin or placebo in the 5- to 6-yr trial were offered open-label fluvastatin in a 2-yr extension to the original study. The association between inflammation markers, high-sensitivity C-reactive protein (hsCRP), and IL-6 on cardiovascular events and all-cause mortality was investigated.

Results: The baseline IL-6 value was 2.9 +/- 1.9 pg/ml (n = 1751) and that of hsCRP was 3.8 +/- 6.7 mg/L (n = 1910). After adjustment for baseline values for established risk factors, the hazard ratios for a major cardiac event and all-cause mortality for IL-6 were 1.08 [95% confidence interval (CI), 1.01 to 1.15, P = 0.018] and 1.11 (95% CI, 1.05 to 1.18, P < 0.001), respectively. The adjusted hazard ratio for hsCRP for a cardiovascular event was 1.10 (95% CI, 1.01 to 1.20, P = 0.027) and for all-cause mortality was 1.15 (95% CI, 1.06 to 1.1.25, P = 0.049).

Conclusions: The inflammation markers IL-6 and hsCRP are independently associated with major cardiovascular events and all-cause mortality in renal transplant recipients.

Figures

Figure 1.
Figure 1.
Association between (A) all-cause death, (B) major cardiovascular events, and (C) cerebrovascular events for quartiles of high-sensitivity C-reactive protein (hsCRP) over the whole range of hsCRP. (D) Association between all-cause death, (E) major cardiovascular events, and (F) cerebrovascular events for quartiles of hsCRP below 5 mg/dl. x-axis represents follow-up time in years. y-axis represents cumulative survival.
Figure 2.
Figure 2.
Association between (A) all-cause death, (B) major cardiovascular events, and (C) cerebrovascular events with IL-6 for quartiles of IL-6. x-axis represents follow-up time in years. y-axis represents cumulative survival.

References

    1. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024–2031, 2003
    1. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5: 2929–2936, 2005
    1. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735–1743, 2000
    1. Rigatto C, Parfrey P: Therapy insight: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2: 514–526, 2006
    1. Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12: 1549–1557, 2001
    1. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 109: II2–II10, 2004
    1. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695, 2005
    1. Vazquez MA, Jeyarajah DR, Kielar ML, Lu CY: Long-term outcomes of renal transplantation: A result of the original endowment of the donor kidney and the inflammatory response to both alloantigens and injury. Curr Opin Nephrol Hypertens 9: 643–648, 2000
    1. Cottone S, Palermo A, Vaccaro F, Mule G, Guarneri M, Arsena R, Vadala A, Cerasola G: Inflammation and endothelial activation are linked to renal function in long-term kidney transplantation. Transpl Int 20: 82–87, 2007
    1. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114: 2047–2055, 2006
    1. Martinez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Seron D, Cruzado JM, Moreso F, Diez-Noguera A, Grinyo JM: Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc 37: 3788–3790, 2005
    1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979, 1997
    1. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599–2610, 2004
    1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207, 2008
    1. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899–1911, 1999
    1. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61: S99–S102. 2002
    1. Lauzurica R, Pastor MC, Bayes B, Hernandez JM, Bonet J, Dolade M, Navarro M, Romero R: Pretransplant inflammation: A risk factor for delayed graft function? J Nephrol 21: 221–228, 2008
    1. Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 344: 726–731, 2001
    1. Bakri RS, Afzali B, Covic A, Sriskantharan R, Bharma-Ariza P, Park WH, Sriharan M, Dalton N, Wierzbicki AS, Crook MA, Goldsmith DJ: Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant 18: 201–204, 2004
    1. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM: Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 43: 502–507, 2004
    1. Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 66: 441–447, 2004
    1. Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 4: 1148–1154, 2004
    1. Winkelmayer WC, Schaeffner ES, Chandraker A, Kramar R, Rumpold H, Sunder-Plassmann G, Fodinger M: A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transpl Int 20: 505–511, 2007
    1. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18: 387–394, 1998
    1. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 61: S103–S108, 2002
    1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648–658, 1999
    1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565, 2002
    1. Kruger B, Boger CA, Schroppel B, Farkas S, Schnitzbauer AA, Hoffmann U, Obed A, Murphy BT, Banas B, Kramer BK: No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transpl Int 21: 452–458, 2008
    1. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG: Genetically Elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897–1908, 2008
    1. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey SG: C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366: 1954–1959, 2005
    1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511, 2003
    1. Kusec V, Smalcelj R, Puretic Z, Szekeres T: Interleukin-6, transforming growth factor-beta 1, and bone markers after kidney transplantation. Calcif Tissue Int 75: 1–6, 2004
    1. Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A: Elevated serum interleukin-6 (IL-6) in solid-organ transplant recipients is positively associated with tissue destruction and IL-6 gene expression in the periodontium. J Periodontol 77: 1871–1878, 2006
    1. Sezer S, Akcay A, Ozdemir FN, Kulah E, Arat Z, Haberal M: Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 18: 722–725, 2004
    1. van Ree RM, Oterdoom LH, de Vries AP, Gansevoort RT, van der Heide JJ, van Son WJ, Ploeg RJ, de Jong PE, Gans RO, Bakker SJ: Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant 22: 246–253, 2007
    1. Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L, Gonzalez-Tableros N, Martin-del-Campo F, Correa-Rotter R, Valera I, Alberu J: Markers of inflammation before and after renal transplantation. Transplantation 80: 47–51, 2005
    1. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79: 914–919, 2005
    1. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109: 1955–1959, 2004
    1. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506–512, 1999
    1. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107–114, 1998
    1. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972–978, 1999
    1. Lowrie EG, Lew NL: Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk. Semin Nephrol 12: 276–283, 1992
    1. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451–459, 2004
    1. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407, 2009
    1. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248, 2005
    1. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74: 1461–1467, 2008
    1. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease—Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60: 451–457, 1995

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren